67. 多発性嚢胞腎 Polycystic kidney disease Clinical trials / Disease details


臨床試験数 : 221 薬物数 : 212 - (DrugBank : 55) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 151

  
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02127437
(ClinicalTrials.gov)
September 19, 20142/4/2014Lanreotide In Polycystic Kidney Disease StudyLanreotide In Polycystic Kidney Disease StudyAutosomal Dominant Polycystic Kidney Disease (ADPKDDrug: Lanreotide;Drug: salineAssistance Publique - Hôpitaux de ParisIPSEN pharmaceutical company, Boulogne-Billancourt, FranceCompleted18 YearsN/AAll159Phase 3France
2NCT01616927
(ClinicalTrials.gov)
June 20126/6/2012Study of Lanreotide to Treat Polycystic Kidney DiseaseThe DIPAK 1 Study: A Randomised, Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in ADPKDAutosomal Dominant Polycystic Kidney Disease (ADPKD)Drug: LanreotideUniversity Medical Center GroningenLeiden University Medical Center;Erasmus Medical Center;Radboud UniversityActive, not recruiting18 Years60 YearsAll300Phase 3Netherlands
3EUCTR2011-005017-37-NL
(EUCTR)
30/05/201221/05/2012To investigate the effect of Lanreotide on renal function decline in ADPKD patientsA randomised, controlled clinical trial assessing the efficacy ofLanreotide to halt disease progression in ADPKD - The DIPAK 1 Study First, to demonstrate whether Lanreotide attenuates progression of the renal phenotype in ADPKD patients as measuredby change in rate of renal function decline and change in renal volume. Second, to demonstrate whether Lanreotidemodifies progression of the liver phenotype in the subset of ADPKD patients with moderate to severe polycystic liverdisease as measured by change in liver volume.
MedDRA version: 14.1;Level: LLT;Classification code 10023433;Term: Kidney polycystic;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Somatuline Autogel
Product Name: Lanreotide
Product Code: BIM 23014
INN or Proposed INN: Lanreotide
Other descriptive name: LANREOTIDE ACETATE
DIPAK ConsortiumNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Netherlands
4NCT01354405
(ClinicalTrials.gov)
May 201113/5/2011Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)The Effect of Lanreotide on Volume of Polycystic Liver and Kidney in Autosomal Dominant Polycystic Kidney DiseasePolycystic Liver DiseaseDrug: LanreotideRadboud UniversityIpsenCompleted18 Years70 YearsBoth43N/ANetherlands
5NCT00771888
(ClinicalTrials.gov)
April 200813/10/2008Open-Label Extension of LOCKCYST TrialOpen-Label Extension of the LOCKCYST Trial, LOCKCYST: Long Acting Lnareotide as as Volume Reducing Treatment of Polycystic LiversPolycystic Liver Disease;Hepatomegaly;Liver Diseases;Polycystic Kidney;Autosomal DominantDrug: lanreotideRadboud UniversityIpsenActive, not recruiting18 Years88 YearsBoth54Phase 2/Phase 3Belgium;Netherlands
6NCT00565097
(ClinicalTrials.gov)
October 200728/11/2007Lanreotide as Treatment of Polycystic LiversLong-Acting Lanreotide as a Volume Reducing Treatment of Polycystic LiversPolycystic Liver Disease;Hepatomegaly;Liver Diseases;Polycystic Kidney, Autosomal DominantDrug: Placebo;Drug: LanreotideRadboud UniversityIpsenCompleted18 Years88 YearsBoth38Phase 2/Phase 3Belgium;Netherlands